Current status of radioimmunotherapy

Steven M. Larson, Chaitanya R. Divgi, Andrew Scott, George Sgouros, Martin C. Graham, Lale Kostakoglu, David Scheinberg, Nai Kong V. Cheung, Jeffrey Schlom, Ronald D. Finn

Research output: Contribution to journalArticle

Abstract

Radioimmunotherapy with radiolabeled monoclonal antibodies is increasingly effective for hematopoietic tumors, with a number of investigators reporting persistent major responses. Radioimmunotherapy for solid tumors has been more difficult and only an occasional major response has been reported and these have so far not been persistent. Toxicity is predominantly hematopoietic, with platelets being most sensitive to the effects of radiation. Even at ultra-high doses (up to 28 mCi/kg of 131I), second organ toxicity has not been reached. Rational approaches to dose planning are becoming possible with improvements in dosimetry, based on quantitative SPECT and PET imaging. Current therapeutic indices for tumor/marrow, the most radiosensitive organ, are in the range of 5-10 to I. This is probably still too low for curative treatment of solid tumors, and further refinements, perhaps based on novel antibody formulations, are needed.

Original languageEnglish (US)
Pages (from-to)785-792
Number of pages8
JournalNuclear Medicine and Biology
Volume21
Issue number5
DOIs
StatePublished - Jul 1994

    Fingerprint

ASJC Scopus subject areas

  • Molecular Medicine
  • Radiology Nuclear Medicine and imaging
  • Cancer Research

Cite this

Larson, S. M., Divgi, C. R., Scott, A., Sgouros, G., Graham, M. C., Kostakoglu, L., Scheinberg, D., Cheung, N. K. V., Schlom, J., & Finn, R. D. (1994). Current status of radioimmunotherapy. Nuclear Medicine and Biology, 21(5), 785-792. https://doi.org/10.1016/0969-8051(94)90050-7